Kyverna Therapeutics, Inc. - KYTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures III, LP | 4.9% | 2,805,426 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures III GP, LLC | 4.9% | 2,805,426 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures, LP | 0.8% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures GP, LLC | 0.8% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | NPV Listed, LLC | 0.4% | 211,400 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures, LLC | 0.4% | 211,400 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michael P. Rubin | 6.1% | 3,466,826 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bain Capital Life Sciences Opportunities III, LP | 5.4% | 3,110,000 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.3% | 3,787,940 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Westlake BioPartners GP I, LLC ("Westlake GP I") | 6.3% | 3,787,940 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") | 1.5% | 869,317 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") | 1.5% | 869,317 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% | 4,657,257 | View |
| Nov 17, 2025 | SCHEDULE 13G | GordonMD Global Investments LP | 7.0% | 3,058,485 | View |
| Nov 17, 2025 | SCHEDULE 13G | GordonMD Long Biased Master Fund LP | 6.2% | 2,735,783 | View |
| Nov 17, 2025 | SCHEDULE 13G | GordonMD Long Biased GP LLC | 6.2% | 2,735,783 | View |
| Nov 17, 2025 | SCHEDULE 13G | Craig D. Gordon | 7.0% | 3,058,485 | View |
| Nov 17, 2025 | SCHEDULE 13G | GordonMD Global Investments GP LLC | 7.0% | 3,058,485 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.